New HCV Therapy Harvoni (Ledipasvir and Sofosbuvir) FDA Approved

The latest therapy for hepatitis C, a combination of Ledipasvir and Sofosbuvir has been FDA approved. Called Harvoni, this is the newest therapy for hepatitis C manufactured by Gilead, and has yet again changed the landscape of how hepatitis C patients are treated. With a cure rate of over 95%, this will give the 4 million patients with hepatitis C the opportunity to be cured of their virus. Very well tolerated with minimal side effects, Harvoni is another interferon-free therapy available for HCV patients